Health News

Gentler Sarcoma Treatment may be at Hand
One of the most common types of childhood cancer is sarcoma, which appears in the soft tissues of the body. About 10 percent of kids with cancer have sarcomas. Recent research has uncovered possible new ways to treat this disease.
Advancements in Treating Advanced Breast Cancers
A great deal of exciting news has been released recently regarding novel drug combinations that extend the lives of patients living with advanced breast cancers. 
Hear No Evil, Touch No Evil?
People who have inherited a form of hearing loss appear to have inherited an increased sensitivity in their sense of touch as well, establishing a genetic link between the two senses.
Masquerading Leukemias
It doesn't happen commonly, though some diseases can present themselves as other diseases. Scientists now know this sometimes happens with two forms of leukemia.
Tumor Invasion Strategies Revealed
What triggers some tumors to begin their invasion of healthy tissue? What gives the marching orders? Scientists now know the cascading events that push brain tumors to start infiltrating.
Science Says Take Your Asthma Medication
Pharmaceutical companies don't just make up dosing instructions on a whim. A new study highlights the importance of using asthma medication as prescribed because it will help reduce symptoms.
Super Cancer Vaccine on the Horizon?
The possibilities for treating a number of cancers - including difficult to treat ones - have just taken a gargantuan leap. An experimental vaccine is showing hugely promising results in animal studies.
Novartis Drug Shows Reduction of Iron Overload
Results from THALASSA , the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade ( deferasirox ) in patients with non-transfusion-dependent thalassemia ( NTDT ), show that Exjade can significantly reduce iron overload. These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego.
Merck Announces Multiple Myeloma Drug Trial Results
Merck  announced today that a Phase III study of Zolinza ( vorinostat ), for investigational use in combination with bortezomib in patients with progressive multiple myeloma , met its primary endpoint, demonstrating a 23 percent reduction in the risk of progression compared to the standard therapy of bortezomib (p=0.01).
Some Multiple Dystrophy Patients Have Increased Cancer Risks
Muscular dystrophy is a debilitating disease on its own. Now patients with the most serious form of the disease are learning they have increased risks of other serious diseases.
<< first133913401341134213431344134513461347last >>

REFINE